Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial - Bonaca, MP; Gutierrez, JA; Cannon, C (Lancet Diabetes Endocrinol, 2018)
et al.